Effect of wet cupping in Hairfall

Therapeutic efficacy of Hijama bil Shart Wet Cupping in the Management of Daal thalab (Alopecia areata) Open label Randomized controlled study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106076

Enrollment

Registered

2026-03-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified

Interventions

Intervention1: Hijama bil Shart (Wet Cupping): Pressure and Heart Rate will be measured for each person. Hijama bil Shart (Wet Cupping) will be performed in sitting position while some feel relaxed in

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed patients of Alopecia areata. 2. Patients between age group of 18 years to 50 years. 3. Patients irrespective of gender. 4. Patients having 1 or more patches on scalp having diameter of greater than 1 cm. 5. Patients having diffuse pattern hair loss. 6. Patients having band pattern hair loss. 7. Patients having hair loss of grade S1, S2, and S3 according to SALT score. 8. Patients having hemoglobin level more than or equal to 10 gm per dl. 9. Patients who have agreed to sign the informed consent form and are willing to follow up as per the study protocol.

Exclusion criteria

Exclusion criteria: 1. Patients having SALT S4, S5 grade hair loss. 2. Patients on another medication for Alopecia areata 1 month prior to study. 3. Patients having any other Auto immune diseases related to Alopecia areata. 4. Patients suffering from systemic illness like uncontrolled diabetes mellitus, uncontrolled hypertension, malignancy, liver and kidney dysfunction. 5. Patients having any bleeding/Coagulation disorders. 6. Patients on any anti-coagulant therapy. 7. Patients of Androgenic Alopecia, tinea capitis. 8. Patients who refuse to give the written consent for the study and unwillingness to come for regular follow up as described in the study plan.

Design outcomes

Primary

Measure	Time frame
1. Change from baseline to 6oth day in the SALT Score 2. Photogarphic assessment on day o and day 60Timepoint: 1. Change from baseline to 6oth day in the SALT Score 2. Photogarphic assessment on day o and day 60	—

Secondary

Measure	Time frame
Change from baseline to 6oth day in the DLQITimepoint: Day 0 and Day 60	—

Countries

India

Contacts

Public ContactDr Mohd Danish

Regional Research Institute Of Unani Medicine Srinagar

drasgarnazir11@gmail.com6005516889

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026